EBV-Related PTLD
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas (NCT05011058) | Viracta Therapeutics, Inc. | 2021-05-28 |
| Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (NCT02973113) | Baylor College of Medicine | 2016-02-16 |
| Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children (NCT02182986) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-08-14 |
Track EBV-Related PTLD automatically
Every clearance here is in the API, with alerts when new ones post.